Safety, immunogenicity, and anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only, or a prime and boost, intramuscular injection of VRON-0200 Over 7,680 ...
Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that its joint venture partner, Virion Therapeutics, has dosed its first patient in the Phase 1b clinical trial of its investigational VRON-0200 ...
PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), a ...
Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...
Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The ...
.Over 8,295 and 821 safety days reported in VRON-0200 alone (n=27), and VRON-0200 combination treated patients (n=7), respectively; VRON-0200 was well tolerated, with no serious treatment-related ...
-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Both Virion Therapeutics and ...
PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results